ConductScience.org, home

Paper8097524

Recombinant interleukin 12 cures mice infected with Leishmania major.

Heinzel FP and 4 others. J Exp Med, 1993. Cited by 734 papers, by iCite.

Cite this record

ConductScience Library. Recombinant interleukin 12 cures mice infected with Leishmania major. Papers, record 8097524. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8097524

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recombinant interleukin 12 cures mice infected with Leishmania major.
PubMed
Journal
J Exp Med
PubMed
Year
1993
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
734
iCite
Relative citation ratio, by iCite
17.2
iCite
Revised in PubMed
2026-01-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Heinzel FPF P
2Schoenhaut DSD S
3Rerko RMR M
4Rosser LEL E
5Gately MKM K

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
InterleukinsMajor topic
Leishmaniasis, CutaneousMajor topic
Animals
Antibodies, Monoclonal
Interferon-gamma
Interleukin-12
Leishmania tropica
Lymph Nodes
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Recombinant Proteins
Spleen
T-Lymphocytes

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
AI-27461NIAID NIH HHSUnited StatesR29AI027461PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13926895Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice.J Immunol1985https://conductscience.org/library/papers/3926895PubMed
21358972Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.J Immunol1992https://conductscience.org/library/papers/1358972PubMed
33782864New perspectives on a subclinical form of visceral leishmaniasis.J Infect Dis1986https://conductscience.org/library/papers/3782864PubMed
42903212Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.J Exp Med1988https://conductscience.org/library/papers/2903212PubMed
52521244Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.J Exp Med1989https://conductscience.org/library/papers/2521244PubMed
62492265Endotoxin-induced serum factor that stimulates gamma interferon production.Infect Immun1989https://conductscience.org/library/papers/2492265PubMed
72522884The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis.Exp Parasitol1989https://conductscience.org/library/papers/2522884PubMed
82499629Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.J Immunol1989https://conductscience.org/library/papers/2499629PubMed
92509562IL-4 inhibits H2O2 production and antileishmanial capacity of human cultured monocytes mediated by IFN-gamma.J Immunol1989https://conductscience.org/library/papers/2509562PubMed
102104918Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.J Exp Med1990https://conductscience.org/library/papers/2104918PubMed
111672545Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers.J Exp Med1991https://conductscience.org/library/papers/1672545PubMed
121831830Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines.J Immunol1991https://conductscience.org/library/papers/1831830PubMed
131717284A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages.Eur J Immunol1991https://conductscience.org/library/papers/1717284PubMed
141684779Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo.Immunol Rev1991https://conductscience.org/library/papers/1684779PubMed
151531351IL-4 induces a Th2 response in Leishmania major-infected mice.J Immunol1992https://conductscience.org/library/papers/1531351PubMed
161350290Cloning and expression of murine IL-12.J Immunol1992https://conductscience.org/library/papers/1350290PubMed
173079789Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.J Immunol1986https://conductscience.org/library/papers/3079789PubMed

Download CSV of references

Cited by197

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 734 citations.

PMIDTitleJournalYearIn PapersSource
40732663Immune-Pathological Correlates of Disease Severity in New-World Kala-Azar: The Role of Parasite Load and Cytokine Profiles.Pathogens2025https://conductscience.org/library/papers/40732663PubMed
40512023Oxygen and immunity to Leishmania infection.Infect Immun2025https://conductscience.org/library/papers/40512023PubMed
40287829An overview of host immune responses against Leishmania spp. infections.Hum Mol Genet2025https://conductscience.org/library/papers/40287829PubMed
38543472New Approaches to Tackling Intractable Issues in Infectious Disease.Microorganisms2024https://conductscience.org/library/papers/38543472PubMed
37885890Leishmania major-derived lipophosphoglycan influences the host's early immune response by inducing platelet activation and DKK1 production via TLR1/2.Front Immunol2023https://conductscience.org/library/papers/37885890PubMed
36579347Humoral response in Leishmaniasis.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/36579347PubMed
36365010Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.Pathogens2022https://conductscience.org/library/papers/36365010PubMed
35025891A profile of research on the parasitic trypanosomatids and the diseases they cause.PLoS Negl Trop Dis2022https://conductscience.org/library/papers/35025891PubMed
34684248Revisiting Persistent Salmonella Infection and the Carrier State: What Do We Know?Pathogens2021https://conductscience.org/library/papers/34684248PubMed
33934238Potential biomarkers of immune protection in human leishmaniasis.Med Microbiol Immunol2021https://conductscience.org/library/papers/33934238PubMed
33841444Host-Directed Therapies for Cutaneous Leishmaniasis.Front Immunol2021https://conductscience.org/library/papers/33841444PubMed
33604564Humoral immunity in leishmaniasis - Prevention or promotion of parasite growth?Cytokine X2020https://conductscience.org/library/papers/33604564PubMed
33415318Unravelling the unsolved paradoxes of cytokine families in host resistance and susceptibility to Leishmania infection.Cytokine X2020https://conductscience.org/library/papers/33415318PubMed
32948646Acute IL-4 Governs Pathogenic T Cell Responses during Leishmania major Infection.Immunohorizons2020https://conductscience.org/library/papers/32948646PubMed
32784615Leishmania Immunity: Advancing Immunotherapy and Vaccine Development.Microorganisms2020https://conductscience.org/library/papers/32784615PubMed
31024534Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.Front Immunol2019https://conductscience.org/library/papers/31024534PubMed
30697312Effects of Cytokine Therapy for Treatment and Prophylaxis of Hydatidosis in Experimental Animal Model (Mice).Iran J Parasitol2018https://conductscience.org/library/papers/30697312PubMed
30257371Monocyte subpopulations as important biomarkers of resistence and susceptibility during experimental infection with Leishmania (Leishmania) major.Biomed Pharmacother2018https://conductscience.org/library/papers/30257371PubMed
29867798Leishmania Hijacks Myeloid Cells for Immune Escape.Front Microbiol2018https://conductscience.org/library/papers/29867798PubMed
29593739STAT6 Mediates Footpad Immunopathology in the Absence of IL-12p40 Following Infection of Susceptible BALB/c Mice With Leishmania major.Front Immunol2018https://conductscience.org/library/papers/29593739PubMed

See all 197 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8097524

GET https://conductscience.org/api/papers/v1/8097524/cited_by?page=2